{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Minimal+Residual+Disease&page=7",
    "query": {
      "condition": "Minimal Residual Disease",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 186,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Minimal+Residual+Disease&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Minimal+Residual+Disease&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T09:54:12.470Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03070093",
      "title": "Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "FMS-like Tyrosine Kinase-3 (FLT3) Mutations"
      ],
      "interventions": [
        {
          "name": "gilteritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-04-20",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 32,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Pembroke Pines, Florida + 23 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03070093"
    },
    {
      "nct_id": "NCT04991103",
      "title": "Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "DaraVRD/DaraVCD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-09-22",
      "completion_date": "2028-08-27",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04991103"
    },
    {
      "nct_id": "NCT01078337",
      "title": "T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia, Lymphocytic, Acute"
      ],
      "interventions": [
        {
          "name": "bone marrow aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood sampling",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 15,
      "start_date": "2002-11",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2010-03-02",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01078337"
    },
    {
      "nct_id": "NCT03494569",
      "title": "Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia in Remission",
        "Hematopoietic Cell Transplantation Recipient",
        "Minimal Residual Disease",
        "Myelodysplastic Syndrome",
        "Secondary Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Total Marrow Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2018-07-06",
      "completion_date": "2027-09-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03494569"
    },
    {
      "nct_id": "NCT04521231",
      "title": "A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B Cell Precursor Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 181,
      "start_date": "2021-01-04",
      "completion_date": "2029-05-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 13,
      "location_summary": "Clovis, California • Duarte, California • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04521231"
    },
    {
      "nct_id": "NCT00267085",
      "title": "Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Minimal Residual Disease"
      ],
      "interventions": [
        {
          "name": "Synthetic Tumor-Specific Breakpoint Peptide Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2005-12",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2012-08-07",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00267085"
    },
    {
      "nct_id": "NCT02275533",
      "title": "Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2015-07-02",
      "completion_date": "2026-10-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02275533"
    },
    {
      "nct_id": "NCT05366881",
      "title": "cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Cancer",
        "Breast Cancer",
        "Bladder Cancer",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Endometrial Cancer",
        "Esophageal Cancer",
        "Stomach Cancer",
        "Head and Neck Cancer",
        "Hepatobiliary Cancer",
        "Leukemia",
        "Lung Cancer",
        "Lymphoma",
        "Multiple Myeloma",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Renal Cancer",
        "Sarcoma",
        "Thyroid Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Adela, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 7000,
      "start_date": "2022-05-03",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 17,
      "location_summary": "Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "New Albany",
          "state": "Indiana"
        },
        {
          "city": "Corbin",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05366881"
    },
    {
      "nct_id": "NCT07566364",
      "title": "Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Mosunetuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-07-09",
      "completion_date": "2030-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07566364"
    },
    {
      "nct_id": "NCT03737955",
      "title": "Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Gemtuzumab Ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2018-11-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-08T09:54:12.470Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03737955"
    }
  ]
}